Abstract
Objective
Methods
Results
Conclusions
Keywords
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to The American Journal of MedicineReferences
- Trends in the incidence of venous thromboembolism during pregnancy or postpartum: a 30-year population-based study.Ann Intern Med. 2005; 143: 697-706
- Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): A multinational open-label randomised trial.Lancet. 2014; 384: 1673-1683
- Venous thromboembolism during pregnancy and the postpartum period: incidence, risk factors, and mortality.Am J Obstet Gynecol. 2006; 194: 1311-1315
- Temporary increase in the risk for recurrence during pregnancy in women with a history of venous thromboembolism.Blood. 2002; 100: 1060-1062
Regitz-Zagrosek V, Roos-Hesselink JW, Bauersachs J, et al. 2018 ESC Guidelines for the management of cardiovascular diseases during pregnancy. 2018;39(34):3165-3241.
- Guidance for the treatment and prevention of obstetric-associated venous thromboembolism.J Thromb Thrombolysis. 2016; 41: 92-128
- American Society of Hematology 2018 guidelines for management of venous thromboembolism: venous thromboembolism in the context of pregnancy.Blood Adv. 2018; 2: 3317-3359
- Cardiovascular management in pregnancy.Circulation. 2015; 132: 1354-1364
- Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy.Blood. 2005; 106: 401-407
- Anticoagulant therapy forvenous thromboembolism during pregnancy: a systematic review and a meta-analysis of the literature.J Thromb Haemost. 2013; 11: 270-281
- Prophylaxis with low-dose low-molecular-weight heparin during pregnancy and postpartum: is it effective?.J Thromb Haemost. 2011; 9: 473-480
- The incidence and risk factors of recurrent venous thromboembolism during pregnancy.Thromb Res. 2014; 134: 240-245
- Low-molecular-weight heparins for thromboprophylaxis and treatment of venous thromboembolism in pregnancy: a systematic review of safety and efficacy.Blood. 2005; 106: 401-407
- Effectiveness and safety of thromboprophylaxis with enoxaparin for prevention of pregnancy-associated venous thromboembolism.J Thromb Haemost. 2019; 17: 1160-1170
- VTE, thrombophilia, antithrombotic therapy, and pregnancy.Chest. 2012; 141: e691S-e736S
- Examining the transplacental passage of apixaban using the dually perfused human placenta.J Thromb Haemost. 2016; 14: 1436-1441
- Rivaroxaban transfer across the dually perfused isolated human placental cotyledon.Am J Obstet Gynecol. 2015; 213: 710.e1-710.e6
- Pregnancy outcome in patients exposed to direct oral anticoagulants - and the challenge of event reporting.Thromb Haemost. 2016; 116: 651-658
- Pregnancy outcome after exposure to the novel oral anticoagulant rivaroxaban in women at suspected risk for thromboembolic events: a case series from the German Embryotox Pharmacovigilance Centre.Clin Res Cardiol. 2016; 105: 117-126
- Efficacy and safety of direct oral anticoagulants during pregnancy; a systematic literature review.Thromb Res. 2018; 169: 123-127
- Outcome of DOAC exposure during pregnancy (…and the problem of event reporting…).Res Pract Thromb Haemost. 2020; 4: 32
- The Danish National Health Service Register.Scand J Public Health. 2011; 39: 34-37
- The Danish National Patient Registry: a review of content, data quality, and research potential.Clin Epidemiol. 2015; 7: 449-490
- Data resource profile: the Danish National Prescription Registry.Int J Epidemiol. 2017; 46 (798-798f)
- The Danish Civil Registration System as a tool in epidemiology.Eur J Epidemiol. 2014; 29: 541-549
- The Danish Medical Birth Register.Eur J Epidemiol. 2018; 33: 27-36
- Positive predictive value of cardiovascular diagnoses in the Danish National Patient Registry: a validation study.BMJ Open. 2016; 6e012832
- Statin use and venous thromboembolism recurrence: a combined nationwide cohort and nested case-control study.J Thromb Haemost. 2014; 12: 1207-1215
- Misclassification in assessment of first trimester in-utero exposure to drugs used proximally to conception: the example of letrozole utilization for infertility treatment.Am J Epidemiol. 2019; 188: 418-425
- Risk of recurrent venous thromboembolism: a Danish nationwide cohort study.Am J Med. 2018; 131: 1067-1074.e4
- Teratogen update: fetal effects after in utero exposure to coumarins overview of cases, follow-up findings, and pathogenesis.Teratology. 2002; 66: 127-140
- Vitamin K antagonists and pregnancy outcome. A multi-centre prospective study.Thromb Haemost. 2006; 95: 949-957
- Linkage between the Danish National Health Service Prescription Database, the Danish Fetal Medicine Database, and other Danish registries as a tool for the study of drug safety in pregnancy.Clin Epidemiol. 2016; 8: 91-95
- Predictive value and completeness of the registration of congenital abnormalities in three Danish population-based registries.Scand J Public Health. 2003; 31: 12-16
- Prophylaxis for venous thromboembolic disease in pregnancy and the early postnatal period.Cochrane Database Syst Rev. 2014; CD001689
- Management of direct oral anticoagulants in women of childbearing potential: guidance from the SSC of the ISTH.J Thromb Haemost. 2016; 14: 1673-1676
Article info
Publication history
Footnotes
Funding: This research was partly funded by an unrestricted grant from the Obel Family Foundation. The sponsor had no role in the study design and conduct; the data collection, management, analysis, and interpretation; the writing of the report; or the decision to submit the paper for publication.
Conflicts of Interest: MS and FS have received consulting fees from Bayer. PBN has received speaking fees from Boehringer Ingelheim, consulting fees from Bayer and Daiichi-Sankyo, and grant support from Bristol-Myers Squibb/Pfizer and Daiichi-Sankyo. JB-W has received research grants and honoraria for lectures and consultancy from Bayer, Bristol-Myers Squibb, Daiichi-Sankyo, Doasense, Pfizer, and Portola. TBL has served as an investigator for Janssen Scientific Affairs, LLC and Boehringer Ingelheim, and has received speaking fees from Bayer, Bristol-Myers Squibb/Pfizer, Boehringer Ingelheim, MSD, and AstraZeneca.
Authorship: MS and FS are the guarantors; they had full access to all data in this study, and take responsibility for the data integrity and the accuracy of the data analysis. All authors contributed to the study design, analyzed and interpreted the data, drafted the article or critically revised it for important intellectual content, and approved the final version. MS: Data curation, formal analysis, funding acquisition, methodology, writing – original draft, review, and editing; FS: Data curation, formal analysis, funding acquisition, methodology, writing – original draft, review, and editing; PBN: Formal analysis, funding acquisition, methodology, writing – original draft, review, and editing; JB-W: Formal analysis, funding acquisition, methodology, writing – original draft, review, and editing; TBL: Formal analysis, funding acquisition, methodology, writing – original draft, review, and editing.
Paper presentation: An abstract based on parts of these data was presented at the European Society of Cardiology Congress 2019, Paris.
